CRXM Taxus Cardium Pharmaceuticals Group Inc

USD 0.00 0.00 0
Icon

Taxus Cardium Pharmaceuticals Group Inc (CRXM) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | OTC
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.0001

0.00 (0.00)%

USD 64.00

N/A

N/A

N/A

Icon

CRXM

Taxus Cardium Pharmaceuticals Group Inc (USD)
COMMON STOCK | OTC
USD 0.00
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 64.00

N/A

USD 0.00

Taxus Cardium Pharmaceuticals Group Inc (CRXM) Stock Forecast

N/A

Based on the Taxus Cardium Pharmaceuticals Group Inc stock forecast from 0 analysts, the average analyst target price for Taxus Cardium Pharmaceuticals Group Inc is not available over the next 12 months. Taxus Cardium Pharmaceuticals Group Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Taxus Cardium Pharmaceuticals Group Inc is Very Bearish, which is based on 0 positive signals and 7 negative signals. At the last closing, Taxus Cardium Pharmaceuticals Group Inc’s stock price was USD 0.0001. Taxus Cardium Pharmaceuticals Group Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.

No recent analyst target price found for Taxus Cardium Pharmaceuticals Group Inc
No recent average analyst rating found for Taxus Cardium Pharmaceuticals Group Inc

Company Overview Taxus Cardium Pharmaceuticals Group Inc

Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an an...Read More

11230 Sorrento Valley Road, San Diego, CA, United States, 92121

3

December

USD

USA

Adjusted Closing Price for Taxus Cardium Pharmaceuticals Group Inc (CRXM)

Loading...

Unadjusted Closing Price for Taxus Cardium Pharmaceuticals Group Inc (CRXM)

Loading...

Share Trading Volume for Taxus Cardium Pharmaceuticals Group Inc Shares

Loading...

Compare Performance of Taxus Cardium Pharmaceuticals Group Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for CRXM

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Taxus Cardium Pharmaceuticals Group Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF
Novo Nordisk A/S +4.27 (+3.40%) USD564.56B 46.25 4.92

ETFs Containing CRXM

Symbol Name CRXM's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Taxus Cardium Pharmaceuticals Group Inc (CRXM) Stock

Stock Target Advisor's fundamental analysis for Taxus Cardium Pharmaceuticals Group Inc's stock is Very Bearish.

Unfortunately we do not have enough data on CRXM's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on CRXM's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on CRXM's stock to indicate if its overvalued.

The last closing price of CRXM's stock was USD 0.00.

The most recent market capitalization for CRXM is USD 64.00.

Unfortunately we do not have enough analyst data on CRXM's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Taxus Cardium Pharmaceuticals Group Inc's stock.

As per our most recent records Taxus Cardium Pharmaceuticals Group Inc has 3 Employees.

Taxus Cardium Pharmaceuticals Group Inc's registered address is 11230 Sorrento Valley Road, San Diego, CA, United States, 92121. You can get more information about it from Taxus Cardium Pharmaceuticals Group Inc's website at https://genebiotherapeutics.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...